Table 4—

Categorization by insulin antibody level (5, 5–25 and >25%) of IAsp-specific, HI-specific, and cross-reactive antibodies during 12 months of treatment in 884 patients with type 1 diabetes (study 1) (9)legend

Time and antibody level (%)IAsp
HI
Antibodies specific to:Antibodies specific to:
IAspHICross-reactingIAspHICross-reacting
Baseline
    n484484484217217217
    ≤5459 (94.8)467 (96.5)174 (36.0)205 (94.5)209 (96.3)69 (31.8)
    5–2524 (5.0)16 (3.3)180 (37.2)12 (5.5)8 (3.7)95 (43.8)
    >251 (0.2)1 (0.2)130 (26.9)0 (0.0)0 (0.0)53 (24.4)
Month 3
    n458458458207207207
    ≤5428 (93.4)442 (96.5)128 (27.9)194 (93.7)199 (96.1)68 (32.9)
    5–2528 (6.1)16 (3.5)156 (34.1)13 (6.3)8 (3.9)85 (41.1)
    >252 (0.4)0 (0.0)174 (38.0)0 (0.0)0 (0.0)54 (26.1)
Month 6
    n490490490219219219
    ≤5457 (93.3)473 (96.5)138 (28.2)205 (93.6)211 (96.3)81 (37.0)
    5–2531 (6.3)17 (3.5)200 (40.8)14 (6.4)8 (3.7)88 (40.2)
    >252 (0.4)0 (0.0)152 (31.0)0 (0.0)0 (0.0)50 (22.8)
Month 9
    n438438438197197197
    ≤5409 (93.4)425 (97.0)132 (30.1)185 (93.9)189 (95.9)62 (31.5)
    5–2528 (6.4)13 (3.0)186 (42.5)12 (6.1)8 (4.1)82 (41.6)
    >251 (0.2)0 (0.0)120 (27.4)0 (0.0)0 (0.0)53 (26.9)
Month 12
    n464464464201201201
    ≤5438 (94.4)450 (97.0)147 (31.7)192 (95.5)193 (96.0)67 (33.3)
    5–2525 (5.4)14 (3.0)192 (41.4)9 (4.5)7 (3.5)80 (39.8)
    >251 (0.2)0 (0.0)125 (26.9)0 (0.0)1 (0.5)54 (26.9)
  • legend

    legend Data are n (%), with n = number of patients with antibody measurements at the specified timepoint. Only patients completing the 12 months observation period are included in the present table.